Anlotinib, Chemo-free Therapy, Colorectal Cancer, First-line Treatment, Immunotherapy, Sintilimab
Conditions
Brief summary
This study is designed to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.
Detailed description
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Sintilimab is a fully human IgG4 monoclonal antibody that binds to programmed cell death receptor-1 (PD-1), thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. In the present study, we design a single-arm, single center Phase II trial to evaluate the efficacy and safety of the combination of Anlotinib and Sintilimab in advanced colorectal cancer as first-line treatment.
Interventions
Anlotinib 12mg oral administration daily d1-d14, q3w; Sintilimab 200mg iv drop d1, q3w
Sponsors
Shanghai Changzheng Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients have histologically or cytologically confirmed advanced or recurrent CRC; * No prior systematic anti-cancer treatment and relapse or metastases was occurred more than 12 months after adjuvant chemotherapy; * Patients have measurable disease as defined by RECIST 1.1 as determined by investigator; * Patient with a history of radiotherapy at least 3 months before on the day of providing consent, but the measurable lesion should not be within the scope of radiotherapy; * Patients with age of 18-75yr; * Patients with a performance status of 0,1or 2 on the Eastern Cooperative Oncology Group.； * Patients with Life expectancy of more than 12 weeks; * Patients must have the ability to understand and sign the written informed consent voluntarily; * Female of childbearing potential who are negative in a pregnancy test within 7 days before enrollment. Both male and female patients should agree to use an adequate method of contraception (total abstinence, an intrauterine device or hormone releasing system, a contraceptive implant and an oral contraceptive) starting with the first dose of study therapy through 120 days after the last dose of study therapy. Duration will be determined when the subject is assigned to treatment.
Exclusion criteria
* Patients with dMMR/MSI-H; * Patients with major surgery or severe trauma within 4 weeks before the first medication; * Patients with hypersensitivity to the components in the study protocol;； * Patients who are ready to give birth or are pregnant; * Patients with brain metastases who are unable to accurately describe the condition; * Patients received immune-suppressive drugs 2 weeks before initial treatment (inhaled cortisol or other steroid hormones≤10 mg/day prednisone or equivalent pharmacophysiologic doses were excluded); * Planned live attenuated vaccine within 4 weeks prior to or during study treatment; * Patients have received anlotinib or anti-PD-1 monoclonal antibody therapy or other therapies that act on T-cell co-stimulation targets or checkpoints; * Within 6 months prior to the start of study treatment, the following diseases appeared: myocardial infarction, severe/unstable angina, NYHA grade 2 or above congestive heart failure, poorly controlled arrhythmias, etc; * Active hepatitis; * Bone marrow, liver and kidney function did not meet the requirements of chemotherapy as follows: * Neutrophil count\<1,500/mm3; * Platelet count \<80,000/mm3; * Total bilirubin \>1.5-times the upper limit of normal; * ALT/AST\>2.5-times the upper limit of normal for patients without liver metastases; (5.0-times the upper limit of normal for patients with liver metastases) * Creatinine \>1.5-times the upper limit of normal; * Patients with cancers other than advanced colorectal cancer within five years prior to the start of treatment in this study. Cervical carcinoma in situ, cured basal cell carcinoma and bladder epithelial tumor were excluded; * History of substance abuse, drug use, alcohol dependence; * Patients without legal capacity or limited civil capacity; * Patients with autoimmune diseases or organ transplantation; * Other situations that the investigator deemed inappropriate for enrollment;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objecitve response rate | Evaluation of tumor burden based on RECIST criteria through study completion, an average of 6 weeks | Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progress Free Survival | Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 6 weeks | Time from treatment beginning until disease progression |
| Overall Survival | From date of treatment beginning until the date of death from any cause, through study completion, an average of 3 weeks | Time from treatment beginning until death from any cause |
| Incidence of Treatment-related adverse Events | Through study completion, an average of 3 weeks | — |
| Deepness of response | Evaluation of tumor burden based on RECIST criteria through study completion, an average of 6 weeks | Investigation of depth of response during first-line treatment |
| Disease control rate | Evaluation of tumor burden based on RECIST criteria through study completion, an average of 6 weeks | Proportion of patients who achieved a complete response, a partial response, or stable diseas |
Countries
China
Outcome results
None listed